Skip to main content
. 2014 Jun 19;12(7):1054–1065. doi: 10.1111/jth.12591

Fig 1.

Fig 1

Representative thrombograms without and with rivaroxaban (3–1090 nmol L−1), melagatran (3–948 nmol L−1), or dabigatran (3–1090 nmol L−1) in normal human platelet-poor plasma (A, C, E) and in protein C-deficient plasma (B, D, F) in the absence of recombinant human soluble thrombomodulin (rhs-TM).